ABOUT THE EXPERT
Lowell B. Anthony,
Professor and Chief
Division of Medical Oncology
Department of Medicine
Member, UK Markey Cancer Center
University of Kentucky
Lowell B. Anthony, MD, FACP, is professor and chief, Division of Medical Oncology, Department of Medicine, at the University of Kentucky in Lexington. He is also a member of the National Cancer Institute–designated UK Markey Cancer Center, which has a top-50 ranking by U.S. News & World Report.
He received his undergraduate degree from King College (currently known as King University) in Bristol, TN, and his medical and postgraduate training in internal medicine, medical oncology, and clinical pharmacology at Vanderbilt University Medical Center in Nashville, TN. Prior to joining the University of Kentucky, he was a professor of medicine at the Louisiana State University Health Sciences Center New Orleans. Dr Anthony is board certified in internal medicine and medical oncology, and he is a fellow of the American College of Physicians.
Dr Anthony maintains a busy clinical practice and research program. He has more than 3 decades of experience in conducting clinical trials that encompass a wide variety of topics and formats, including investigator-initiated phase 1/2 clinical trials. He has also participated in many phase 3 registrational and cooperative group trials, with results presented at national and international forums and published in peer-reviewed journals. He has more than 150 publications and is an active member of numerous professional medical societies, including the American Society of Clinical Oncology, the American Federation for Medical Research, the American Association for Cancer Research, SWOG, the Southern Society for Clinical Investigation, and the Multinational Association of Supportive Care in Cancer. He was also a founding member of the North American Neuroendocrine Tumor Society.
He has served on US Food and Drug Administration orphan drug grants and National Institutes of Health SPORE grant review panels. His major professional interests are focused on the study and management of neuroendocrine tumors, with a special focus on developing hepatic locoregional tumor debulking protocols, radiopharmaceutical therapies, and novel somatostatin congener formulations, as well as overcoming drug resistance.